Alto Neuroscience Inc

Alto Neuroscience’s Q3 2025 results reveal FDA‑approved ALTO‑207 for TRD, strong PK data for ALTO‑100/101, and $184 M cash to fund 2026‑2028 milestones, positioning it as a precision psychiatry leader.

Alto Neuroscience, a clinical-stage biopharmaceutical company, aims to revolutionize mental health treatment with its innovative approach, but faces financial uncertainty and high stakes as it prepares to showcase its vision at investor conferences.